CUA 2024 | Dr. Eamonn Rogers: Patient-Centered Care and Exploring Future Strategies for Prostate Cancer

CUA 2024 | Dr. Eamonn Rogers: Patient-Centered Care and Exploring Future Strategies for Prostate Cancer

2024.10.21
Prostate cancer is a common malignant tumor in elderly men. However, with continuous advancements in diagnostic and treatment strategies, patient survival rates have improved, and patient-centered care has become a key focus in oncology. During the recent CUA Annual Meeting, Urology Frontier invited Dr. Eamonn Rogers from the National University of Ireland to share his thoughts on the future of prostate cancer research, the importance of patient-reported outcomes (PROs), and evolving models of care to meet modern medical challenges.
CUA 2024 | Dr. Jeremy Teoh: Addressing Unmet Needs in NMIBC and Exploring Advanced Diagnostic and Treatment Strategies

CUA 2024 | Dr. Jeremy Teoh: Addressing Unmet Needs in NMIBC and Exploring Advanced Diagnostic and Treatment Strategies

2024.10.21
Bladder cancer is one of the most common malignant tumors among the Chinese population, with 75% of cases classified as non-muscle invasive bladder cancer (NMIBC), which has a high postoperative recurrence rate. What are the unmet diagnostic and treatment needs of NMIBC patients? Which research findings may change future clinical practice for NMIBC? During the recent CUA Annual Meeting, Urology Frontier invited Dr. Jeremy Teoh from The Chinese University of Hong Kong to discuss the current unmet needs in NMIBC, the factors influencing recurrence, and the latest research developments that could potentially change clinical practice.
ESMO 2024丨Dr. Fufu Zheng: Progress in Urologic Cancer Research and Explorations Likely to Change Clinical Practice for Advanced Renal Cancer

ESMO 2024丨Dr. Fufu Zheng: Progress in Urologic Cancer Research and Explorations Likely to Change Clinical Practice for Advanced Renal Cancer

2024.10.21
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting is being held from September 13-17 in Barcelona, Spain. Several key studies in the field of urologic cancers have attracted significant attention at the conference. Urology Frontier invited Dr. Fufu Zheng from the Department of Urology at The First Affiliated Hospital , Sun Yat-sen University to provide in-depth analysis of the major research findings presented at the conference. Professor Zheng shared his team’s latest breakthroughs in the field of urology, particularly regarding the frontier advancements in combination therapies for advanced renal cell carcinoma (RCC), while also offering insights into the promising future of RCC treatment.
Revolutionizing NSCLC Treatment: Dr. Baohui Han and Dr. Mitsudomi Unveil New Frontiers in Immunotherapy Strategies

Revolutionizing NSCLC Treatment: Dr. Baohui Han and Dr. Mitsudomi Unveil New Frontiers in Immunotherapy Strategies

2024.10.20
The 27th National Clinical Oncology Conference and 2024 CSCO Academic Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. During this event, Dr. Tetsuya Mitsudomi, who has led several large-scale immunotherapy clinical trials, gave an academic report on the latest progress in immunotherapy for NSCLC. Oncology Frontier invited Dr. Baohui Han from Shanghai Chest Hospital to have an in-depth conversation with Dr. Tetsuya Mitsudomi from Kindai University School of Medicine in Japan. They shared insights on decision-making strategies for perioperative treatment, prognostic biomarkers, and managing adverse events in NSCLC immunotherapy.
ESMO 2024 | Dr. Wei Yu: Advances in Perioperative Immunotherapy and Combined Immunotherapy for Muscle-Invasive Urothelial Carcinoma Patients

ESMO 2024 | Dr. Wei Yu: Advances in Perioperative Immunotherapy and Combined Immunotherapy for Muscle-Invasive Urothelial Carcinoma Patients

2024.10.20
Research has shown that nearly 50% of patients with muscle-invasive urothelial carcinoma (MIUC) will experience recurrence with distant metastases. Therefore, exploring perioperative treatments for muscle-invasive bladder cancer (MIBC) is crucial to improving patient outcomes. The 2024 European Society for Medical Oncology (ESMO) Congress, held from September 13 to 17 in Barcelona, Spain, highlighted several advances in perioperative immunotherapy and combination immunotherapy for MIUC patients. Dr. Wei Yu and Dr. Qi Tang from Peking University First Hospital shared their insights on this important topic.
Dr. Hua Wang: New Approaches in Marginal Zone Lymphoma Treatment – Rethinking Chemotherapy-Free and Combination Strategies丨The 5th Tianjin International Lymphoma Symposium

Dr. Hua Wang: New Approaches in Marginal Zone Lymphoma Treatment – Rethinking Chemotherapy-Free and Combination Strategies丨The 5th Tianjin International Lymphoma Symposium

2024.10.20
From September 6-8, 2024, the 5th Tianjin International Lymphoma Symposium was successfully held. The conference featured twelve specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for promoting international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Hua Wang from the Sun Yat-sen University Cancer Center to review the latest treatment strategies for marginal zone lymphoma (MZL).